SCYB.V - Scythian Biosciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
3.73
+0.23 (+6.57%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.50
Open3.40
Bid3.70 x 0
Ask3.77 x 0
Day's Range3.40 - 3.78
52 Week Range1.01 - 9.92
Volume211,835
Avg. Volume187,868
Market Cap109.414M
Beta4.48
PE Ratio (TTM)N/A
EPS (TTM)-1.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire5 days ago

    Scythian Announces Strategic Sale of Latin American and Caribbean Assets in $193,000,000 Deal to Aphria

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that it has entered into a strategic deal with Aphria Inc. It is expected that the Company’s strategic relationship with Aphria will provide leverage for early stage investments in emerging international markets.

  • GlobeNewswire9 days ago

    Scythian Biosciences Announces Positive Pre-Clinical Data on the Safety and Efficacy of Cannabis Derived Combination Therapy for Mild to Moderate Traumatic Brain Injury

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) and its partners at the University of Miami Miller School of Medicine are pleased to announce the results of a pre-clinical study evaluating the safety and efficacy of a cannabis derived combination therapy in the treatment of mild to moderate traumatic brain injury (TBI) in rodents. The pilot study indicates an improvement in the cognitive functions of animals treated with a cannabinoid (CBD) derived combination therapy compared to being treated with a vehicle, CBD alone, and HU211 alone. Further, there were no adverse effects from either the combination therapy (CBD + HU211) or the individual components observed by scientists at the University of Miami Miller School of Medicine.

  • GlobeNewswire13 days ago

    Scythian Biosciences Corp Announces Colcanna SAS as one of the Industry’s First to Receive Key Cannabis Licences for the Cultivation, Extraction, Production and Research of Medical Cannabis for the Colombian Local Market and Export to International Markets

    TORONTO, July 09, 2018-- Scythian Biosciences Corp. is pleased to announce that Colombian-based Colcanna SAS, the pending acquisition by Scythian, has received additional licences by the Ministry of Health ...

  • GlobeNewswirelast month

    Grit Capital launches GritCAMP Immersive Investment Conference in Muskoka July 25-27th 2018

    Grit Updates the Market on Recent Corporate Initiatives & Milestones. TORONTO, June 22, 2018-- GRIT CAPITAL INC. a capital markets advisory firm known for its aggressive“ out of the box” thinking to capture ...

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Name Change to SOL Global Investments Corp.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that the Company will be changing its name from “Scythian Biosciences Corp.” to “SOL Global Investments Corp.” The Company will put the name change resolution before its shareholders at its next scheduled annual general meeting, which will be sometime in August 2018. The name change is also subject to approval by the TSX Venture Exchange (“TSXV”).

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces ColCanna SAS’ Receipt of Licence to Cultivate and Import CBD into Colombia

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that Colombian-based ColCanna SAS (“ColCanna”), a company that Scythian is in the process of acquiring, has received a licence for the cultivation and importation of non-psychoactive cannabis (“CBD”) by the Ministry of Justice and Law of Colombia. Additionally, ColCanna has entered into an exclusive international supply agreement for Colombia (the “Supply Agreement”) with Aphria Inc. (APH.TO) (“Aphria”), a prominent Canadian low-cost producer of medical cannabis.

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Binding Agreement for Argentinian Acquisition of ABP

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that the Company has entered into a business combination agreement (the "Agreement") with MMJ International Investments Inc. (“MMJ” or “MMJ International”), owner of Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina. ABP also holds a license to import CBD oil into Argentina (the “License”).  Under the terms of the Agreement, Scythian will acquire all of the issued and outstanding common shares of MMJ by way of a three-cornered amalgamation (the “Transaction”) whereby MMJ will amalgamate with a wholly-owned subsidiary of the Company.

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Licensing Agreement With Isodiol International Inc.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that it has signed a letter agreement (the “Agreement”) with Isodiol International Inc. (“Isodiol”), (CSE:ISOL) a market leader in pharmaceutical grade phytochemical compounds and an industry leader in the manufacturing and development of CBD consumer products, to import and distribute Isodiol products to certain countries in the Caribbean, Central America, and South America, including Argentina, Colombia and Jamaica. Scythian has also committed to invest $2,000,000 into Isodiol, in exchange for 2,739,726 units in Isodiol (“Units”), with each Unit consisting of one common share of Isodiol (“Common Share”) and one whole Common Share purchase warrant (“Warrant”).

  • GlobeNewswire3 months ago

    Scythian Announces Marigold’s Exclusive Agreement with Jamaica’s Peter Tosh Museum

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that Jamaica-based Marigold Projects Jamaica Ltd. (“Marigold”), a company that Scythian is in the process of acquiring a 49% interest in, has signed an exclusive sponsorship agreement with the world-renowned Peter Tosh Museum (the “Museum”) in Kingston, Jamaica. Under the terms of the agreement, Marigold will become the exclusive cannabis dispensary partner of the Museum.

  • GlobeNewswire3 months ago

    Scythian Biosciences Announces Extension of Letter of Intent

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) announced today that the Company has signed an agreement to extend its previously announced letter of intent to acquire MMJ International Investments Inc. (“MMJ”), the sole shareholder of ABP S.A. (“ABP”), an Argentina-based pharmaceutical import and distribution company pursuing medical cannabis opportunities in South America. The agreement extends the deadline for negotiating and entering into a definitive agreement with MMJ from April 30, 2018, to May 11, 2018.

  • GlobeNewswire3 months ago

    Scythian Biosciences Corp. Announces the Appointment of European Cannabis Leader Rob Reid of Prohibition Partners as CEO

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) announced today that it has appointed Rob Reid as CEO, George Scorsis as Chairman of the Board of Directors and that it has reinstated Roger Rai to the Board of Directors effective April 25, 2018. In connection with these appointments, Jonathan Gilbert will be stepping down as CEO and will take on a new role of managing the University of Miami partnership. “I am extremely excited to be appointed as CEO of Scythian,” said Rob Reid.

  • CNW Group3 months ago

    IIROC Trading Resumption - SCYB

    VANCOUVER , April 9, 2018 /CNW/ - Trading resumes in: Company: Scythian Biosciences Corp. TSX-Venture Symbol: SCYB Resumption (ET): 14:30 IIROC can make a decision to impose a temporary suspension (halt) ...

  • CNW Group3 months ago

    IIROC Trading Halt - SCYB

    VANCOUVER , April 9, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Scythian Biosciences Corp TSX-Venture Symbol: SCYB Reason: At the Request of the Company Pending News Halt Time ...

  • CNW Group3 months ago

    IIROC Trading Resumption - SCYB

    VANCOUVER , April 9, 2018 /CNW/ - Trading resumes in: Company: Scythian Biosciences Corp TSX-Venture Symbol: SCYB Resumption (ET): 10:00 AM IIROC can make a decision to impose a temporary suspension (halt) ...

  • CNW Group3 months ago

    IIROC Trading Halt - SCYB

    VANCOUVER , April 9, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Scythian Biosciences Corp TSX-Venture Symbol: SCYB Reason: At the Request of the Company Pending News Halt Time ...

  • CNW Group4 months ago

    IIROC Trading Resumption - SCYB

    VANCOUVER , March 22, 2018 /CNW/ - Trading resumes in: Company: Scythian Biosciences Corp. TSX-Venture Symbol: SCYB Resumption (ET): 11:45 AM IIROC can make a decision to impose a temporary suspension ...

  • PR Newswire4 months ago

    IIROC Trading Resumption - SCYB

    VANCOUVER , March 22, 2018 /CNW/ - Trading resumes in: Company: Scythian Biosciences Corp. TSX-Venture Symbol: SCYB Resumption (ET): 11:45 AM IIROC can make a decision to impose a temporary suspension ...

  • CNW Group4 months ago

    IIROC Trading Halt - SCYB

    VANCOUVER , March 22, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Scythian Biosciences Corp. TSX-Venture Symbol: SCYB Reason: At the Request of the Company Pending News Halt Time ...